Stryker announced its plans to acquire the company in June. Artelon’s products enhance biological and mechanical ligament and tendon reconstruction and have been used in more than 60,000 cases globally.
“This acquisition strengthens our competitive edge,” Tim Lanier, president of Stryker’s trauma and extremities division, said in the release. “Leveraging Artelon’s unique synthetic technology and extensive expertise positions us to continue driving innovation and solidify our leadership in the foot and ankle and sports medicine segments.”
